| Author(s) |
Poespoprodjo JR
Douglas NM
Ansong D
Kho S
Anstey, Nicholas
|
| Publication Date |
2023-12-16
|
| Abstract |
Malaria is resurging in many African and South American countries, exacerbated by COVID-19-related health service disruption. In 2021, there were an estimated 247 million malaria cases and 619 000 deaths in 84 endemic countries. Plasmodium falciparum strains partly resistant to artemisinins are entrenched in the Greater Mekong region and have emerged in Africa, while Anopheles mosquito vectors continue to evolve physiological and behavioural resistance to insecticides. Elimination of Plasmodium vivax malaria is hindered by impractical and potentially toxic antirelapse regimens. Parasitological diagnosis and treatment with oral or parenteral artemisinin-based therapy is the mainstay of patient management. Timely blood transfusion, renal replacement therapy, and restrictive fluid therapy can improve survival in severe malaria. Rigorous use of intermittent preventive treatment in pregnancy and infancy and seasonal chemoprevention, potentially combined with pre-erythrocytic vaccines endorsed by WHO in 2021 and 2023, can substantially reduce malaria morbidity. Improved surveillance, better access to effective treatment, more labour-efficient vector control, continued drug development, targeted mass drug administration, and sustained political commitment are required to achieve targets for malaria reduction by the end of this decade.
|
| Affiliation |
Centre for Child Health and Department of Child Health, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Timika Malaria Research Facility, Papuan Health and Community Development Foundation, Timika, Indonesia; Mimika District Hospital and District Health Authority, Timika, Indonesia; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia. Electronic address: didot2266@yahoo.com.
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia; Department of Infectious Diseases, Christchurch Hospital, Te Whatu Ora Waitaha, Christchurch, New Zealand; Department of Medicine, University of Otago, Christchurch, New Zealand.
School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Timika Malaria Research Facility, Papuan Health and Community Development Foundation, Timika, Indonesia; Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia; Department of Infectious Diseases, Royal Darwin Hospital, Darwin, NT, Australia.
|
| Citation |
Lancet. 2023 Dec 16;402(10419):2328-2345. doi: 10.1016/S0140-6736(23)01249-7. Epub 2023 Nov 2.
|
| Pubmed ID |
https://pubmed.ncbi.nlm.nih.gov/37924827/?otool=iaurydwlib
|
| Link | |
| Volume |
402
|
| Subject |
Pregnancy
Female
Animals
Humans
*Antimalarials/therapeutic use
*Malaria/drug therapy/epidemiology/prevention & control
*Malaria, Vivax/drug therapy
Plasmodium falciparum
*Insecticides/therapeutic use
*Malaria, Falciparum/drug therapy
Drug Resistance
|
| Title |
Malaria.
|
| Type of document |
Journal Article
|
| Entity Type |
Publication
|
| Name | Size | format | Description | Link |
|---|